thrombosis

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs<a href="https://solaci.org/en/2021/08/13/the-long-marathon-of-ultrathin-vs-2nd-generation-thin-strut-des/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600&nbsp;patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting<a href="https://solaci.org/en/2021/07/13/novel-des-technology-promises-to-become-the-next-des-generation/" title="Read more" >...</a>

TAVI en insuficiencia aórtica pura

TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is safe and effective. These finding are of crucial importance to the definite adoption of TAVR in the lower risk, younger population.&nbsp; Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in severe aortic stenosis treatment.&nbsp; Technological innovation<a href="https://solaci.org/en/2021/07/06/tavr-durability-becomes-irrelevant-after-transit-outcomes/" title="Read more" >...</a>

TAVI SURAVI

European Consensus on Antithrombotic Management in TAVR

All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR). While thrombotic and hemorrhagic complications have diminished over time—as both the technique and the devices have been perfected—, they still remain as common adverse events in TAVR.&nbsp; Recommendations in the 2017 European Guidelines were<a href="https://solaci.org/en/2021/06/28/european-consensus-on-antithrombotic-management-in-tavr/" title="Read more" >...</a>

Miocardiopatía hipertrófica: análisis de una serie histórica

Differences in American and European Atrial Fibrillation Guidelines

The recent publication of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) guidelines provided an important update on multiple aspects of the management of atrial fibrillation (AF). However, these guidelines differ in terms of management and recommendation levels. As it might be expected, most differences arose in intermediate cases—both guidelines<a href="https://solaci.org/en/2021/06/07/differences-in-american-and-european-atrial-fibrillation-guidelines/" title="Read more" >...</a>

Nuevo dispositivo para medición del FFR permite cruzar la lesión con nuestra guía preferida

FLOWER-MI: FFR vs. Angiography for Complete Revascularization in Infarction

Functional assessment with fractional flow reserve (FFR) was not better than conventional angiography to guide complete revascularization in patients with multivessel lesions in a setting of ST-segment elevation myocardial infarction and successful primary angioplasty. These results were published in the New England Journal of Medicine (NEJM) and presented during the American College of Cardiology (ACC)<a href="https://solaci.org/en/2021/06/07/flower-mi-ffr-vs-angiography-for-complete-revascularization-in-infarction/" title="Read more" >...</a>

EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development

According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of target vessel failure vs. 2nd generation drug eluting stents (DES). This advantage was driven by fewer clinically justified reinterventions.&nbsp; This study was published in the European Heart Journal and simultaneously presented at EuroPCR 2021 Scientific Sessions. Ultrathin struts<a href="https://solaci.org/en/2021/05/26/europcr-2021-ultrathin-struts-consolidate-as-next-des-development/" title="Read more" >...</a>

EuroPCR 2021 | FUTURE II: las plataformas bioabsorbibles vuelven recargadas

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds.&nbsp; Read also:<a href="https://solaci.org/en/2021/05/26/europcr-2021-future-ii-bioresorbable-scaffolds-reloaded/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Very Short Dual Antiplatelet Therapy after Complex PCI

The 1-month outcomes of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy were comparable to 12-month DAPT in patients with both simple and complex PCI. There was no significant interaction between DAPT period and procedure difficulty.&nbsp; This is a post hoc study of the STOPDAPT-2 that looked at the complex PCI patient subgroup.&nbsp;&nbsp; It is<a href="https://solaci.org/en/2021/05/24/very-short-dual-antiplatelet-therapy-after-complex-pci/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin&nbsp;K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>

Top